Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around
Principal Investigator
by Caitlin Costello, MD (ucsd)
Headshot of Caitlin Costello
Caitlin Costello

Description

Summary

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

Official Title

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)

Details

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

The drugs being used in this study are daratumumab ixazomib, pomalidomide, and dexamethasone. Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide, and dexamethasone are standard drugs that can change and regulate the immune system and may stop cancer cells from growing. Both Ixazomib and Daratumumab are approved for use in Multiple Myeloma, but not in this combination.

Keywords

Relapsed/Refractory Multiple Myeloma, multiple myeloma, Daratumumab, Pomalidomide, Ixazomib, Dexamethasone, cancer, Phase 2, Darzalex, Pomalyst, Ninlaro, Decadron, Plasma Cell Neoplasms, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML), ixazomib, daratumumab, pomalidomide and dexamethasone

Eligibility

Location

  • UCSD Moores Cancer Center
    La Jolla California 92093 United States

Lead Scientist at University of California Health

  • Caitlin Costello, MD (ucsd)
    As a member of the Division of Blood and Marrow Transplantation, Dr Costello is dedicated to providing excellent care for patients with a variety of hematologic malignancies, with a specific focus in lymphoproliferative disorders and bone marrow transplantation. Dr Costello’s research interests focus particularly on the refinement of the management and treatment of multiple myeloma.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT03590652
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 46 study participants
Last Updated